Chief Executive Officer
Earl M. (Duke) Collier, Jr. is CEO of 480 Biomedical and serves as executive chairman of Arsenal Medical. For many years, Mr. Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare, a partner at the Washington, DC-based law firm of Hogan and Hartson (now Hogan Lovells) and as Deputy Administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Mr. Collier sits on the boards of 480 Biomedical, Arsenal Medical, Capricor, Transmedics and Newton-Wellesley Hospital. He earned a Bachelor of Arts at Yale University and received a law degree from the University of Virginia Law School.
Maria Palasis, Ph.D.
Executive Vice President and Chief Technology Officer
Prior to joining 480 Biomedical, Dr. Palasis was R&D director at Boston Scientific, where she managed a portfolio of external biotech and medical device investments and was responsible for the development of new convergence products. Dr. Palasis was as an early member of the team that created the TAXUS® drug-eluting stent, the single most important revenue generator for Boston Scientific at $3B/year. She held a number of positions within Boston Scientific that included strategic planning for the development of advanced combination therapies, managing alliances through clinical trials, and building and directing the company’s centralized infrastructure for the biological testing of drug eluting stent technologies. Maria received her Bachelor of Science and doctorate in chemical engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.
Vice President, Operations
Prior to joining 480 Biomedical, Mr. Knox was the vice president of quality assurance and clinical quality at Boston Scientific, where he was responsible for the development of quality systems for the clinical organization, re-creation of post-market surveillance processes and development of analytical infrastructure for the successful TAXUS® product. Mr. Knox has 22 years of experience in the design, development and manufacturing of medical devices with Becton Dickinson, USCI, Medtronic and Boston Scientific. His experience spans large-scale automated manufacturing, highly specialized research and development prototypes, innovative process development, characterization and process validation. Mr. Knox holds a Bachelor’s degree in engineering from University College Dublin and a master’s degree in business administration from Assumption College.
Blaine McKee, Ph.D.
Executive Vice President and Chief Business Officer
Prior to joining 480 Biomedical, Dr. McKee was SVP of Strategic Development at Genzyme, where he led global business development activities for the Organ Transplant, Oncology and Multiple Sclerosis business units. During his 15-year tenure at Genzyme, Dr. McKee played a critical role in the evaluation, planning and execution of several major acquisitions, helping to grow the Genzyme Oncology franchise from an early-stage research operation to an $800 million global business. Blaine holds a PhD in organic chemistry from the Massachusetts Institute of Technology, an MBA from the MIT Sloan School of Management, and a Bachelor’s degree in chemistry from Colorado State University.